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Message from the President

M

any of the most intriguing scientific discoveries raise more
questions than they answer. Indeed, reading this issue of Search,
one is struck by how major new findings and lines of investigation
at The Rockefeller University have their roots in puzzles that first arose as a
result of discoveries made decades ago.
In 1911, for example, Rockefeller scie1;tist Peyton Rous discovered the
first virus that could cause cancer. It was only last year, however, that the
laboratory of John Kuriyan was able to
visualize the 3-D structure of a protein that,
when defective, enables the virus to trigger
tumor growth. The structure now allows
researchers to ask far more precise
questions about how the protein works in
both its normal and cancerous forms.
In 1952, the British physiologists
J--Iodgkin and Huxley postulated that nerve
impulses were generated by the movement
of sodium and potassium ions through
specialized filters, or "channels," embedded
in the surface of nerve cells. Earlier this
year, in a historic achievement, the labora
tory of Roderick MacKinnon used X-ray
crystallography to solve the 3-D structure
of a potassium ion channel protein. This finding resolves the basis of the
selectivity of the channel for potassium ions. At the same time, it raises new
questions about how ion channels generate the ordered electrical impulses
that underlie our perceptions, movements and thoughts.
Three other articles in this issue describe critical studies of gene replication,
genetic control of sleep-wake cycles and the signals that form the nervous
system during embryogenesis. These discoveries, as in the two examples
mentioned above, are simultaneously yielding answers to classic scientific
enigmas and are serving as gateways for fundamental new explorations into
life and disease processes.

TORSTEN N. WIESEL, PRESIDENT
SEARCH
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SEARCH profiles three faculty members
and their research.

Michael O'Donnell
Tinkering with the gears in the machinery of life
BY

JOSEPH BONNER

Roderick MacKinnon
Poring over the mysteries of ion channels
BY

N EERAJA

SANKARAN

Ali Hemmati-Brivanlou
Challenging the concept of embryonic
cell fate determination
BY LJRMILA RANADIVE

CLOCKWISE FROM TOP LEFT: Michael O'Donnell, Roderick

MacKinnon, Ali Hemmati-Brivanlou.
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LEFT: Professorsjohn Kuriyan (left)
and Hidesaburo Hanafusa.
BELOW: The fruit fly Drosophila provides clues
to the regulation of circadian rhythms.
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Keeping time with biology
BY LJRMILA RANADIVE
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A century of cancer research at Rockefeller
BY N EERAJA SAN KARAN
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Science and other news from The Rockefeller University
campus
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ince the institution's
earliest days, investigators
at The Rockefeller
l.Jniversity have pushed
the boundaries of science to expand
our knowledge of the living world,
· making seminal contributions in
such areas as neuroscience and

FELLER UNIVERSITY
immunology and pioneering new
fields such as cell and molecular
biology. Today, university researchers
continue to seek answers to many
basic questions, from how healthy
cells turn cancerous to why certain
cells form one tissue but not another.
From its inaugural days as The
Rockefeller Institute for Medical
Research, the university has grown to
emcompass more than 80 laboratories,
headed by some of the world's leading
scientists. Highlighted here is the
work of three of them.
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Michael O'Donnell

laboratory: DNA Replication
area of study: Mechanisms of DNA replication in bacteria and humans

tinkering
machinery life
WITH tHE GEARS IN THE
OF

I

n the world of proteins, form follows function,
as these molecules bend and twist into the varied
shapes that enable them to perform some of the
most crucial operations in the living cell. Professor
Michael O'Donnell, head of the Laboratory of DNA
Replication and an investigator with the Howard
Hughes Medical Institute, studies the various proteins
that direct perhaps the most important function in
the cells of bacteria and humans-the copying of
DNA during cell division-to gain new insights into
the development of abnormal cells and to identify
molecular targets for halting diseases such as cancer.
Before any cell divides, it must accurately copy its
DNA and the genetic information carried within it,
giving each new cell a complete set of instructions on
how to live and function. "The elegantly simple
structure of DNA initially suggested that the replica
tion process should also be simple," says O'Donnell.
"But over time, the study of this process has shown
that nothing could be further from the truth."-+
BY JOSEPH BONNER
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completed
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The structure of DNA-the so
called double helix that James
Watson and Francis Crick teased
out in 1953-is made up of four
building blocks called nucleotides.
Represented by the letters A, T, G
and C, the nucleotides pair-A
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with T, C with G-to form limitless
combinations along each mirror
image strand of the double helix.
The sequence of the letters in this
alphabet determines the biological
messages that differentiate all living
organisms .

With the discovery of DNA's com
plementary structure, scientists
suggested that for DNA to copy
itself into new cells, the double
helix might separate into individual
strands, with each strand acting as a
template for the creation of a new

ILLUSTRATION BY TERESE WINSLOW

complementary strand.
Little was known about the
mechanisms behind DNA replica
tion until the late 1950s, when
Stanford University's Arthur
Kornberg isolated an enzyme from
the baterium E. coli that he called
DNA polymerase. (For this discov
ery he shared the 1959 Nobel Prize
in physiology or medicine.)
Polymerase was long thought to

blage called a clamp loader places
the� subunit on each fragment.
Dubbed a "sliding clamp," the�
subunit completely encircles the
fragment's double helix and freely
slides along the DNA surface, tether
ing the polymerase machinery to the
DNA for rapid synthesis.
The clamp loader quickly moves
from fragment to fragment, placing a
clamp on each primed segment.

processes as the repair of DNA. He
also works on piecing together the
replication process in humans.
Because evolution conserved the
molecular machinery in bacteria,
yeast and people, many of the
components are similar albeit more
complex. "The polymerase in
humans is very similar to the one in
E. coli, but there are important dif
ferences," says O'Donnell. "Several

"The elegantly simple structure of DNA sugge.sts that the replication process
should also be simple. But nothing could be further from the truth."
-MICHAEL O'DONNELL

be the main enzyme responsible for
replication in E. coli, but scientists
now know that more than a dozen
proteins, known collectively as the
replisome, work in concert to rapid
ly and accurately duplicate bacterial
chromosomes.
The replisome comprises many
enzymes, including the primase,
the helicase and DNA polymerase
(see figure). In bacteria, replication
begins at a distinct point in the
chromosome called the origin,
where several proteins gather to
unwind and unzip the DNA into
separate strands.
The helicase encircles the
replication fork, a Y-shaped region,
or growing point, that translocates
the parental DNA helix as it
unwinds. The polymerase moves
with the replication fork, but the
DNA polymerase only replicates in
one direction, and as a result, only
one strand, called the leading
strand, is copied in one continuous
segment.
The other strand, called the lag
ging strand, is replicated in short
pieces called Okazaki fragments. At
the replication fork, the primase
produces a short stretch of RNA to
"prime" the synthesis of each
Okazaki fragment. A protein assem-

The polymerase comes in and works
with the clamp to extend the frag
ment. The clamp loader disengages
and moves on to the next primed
fragment.
"This is where the polymerase
really begins to look like a machine,"
says O'Donnell. "You can think of it
as a ratchet, where it produces
the strand by making a fragment,
popping off the helix, going back,
making a fragment, popping off,
again and again."
A major part of O'Donnell's
research involves determining what
the gears in the DNA replication
machinery look like. Since the early
1990s, when he was at Cornell
University Medical College,
O'Donnell has collaborated with RU
Professor and HHMI Investigator
John Kuriyan to solve the three
dimensional structures of many
of the proteins that replicate
DNA in bacteria. To date, the two
scientists and their colleagues have
determined the structures of six
. replication proteins, including the
ring-shaped� subunit and subunits
of the clamp loader.
O'Donnell is working on under
standing how the bacteral replica
tion machinery interfaces with
other proteins that perform such

of the human replication proteins
have yet to be discovered. For exam
ple, it is still uncertain what enzyme
performs the helicase function,
although most scientists expect one
will be found."
O'Donnell also expects to find
differences in the events that take
place at the origin. Yeast chromo
somes, like those in humans, are
linear rather than circular. Scientists
have identified specific origins in
yeast, but the human origin
complex remains elusive.
As O'Donnell and other
scientists uncover more details
about human DNA replication,
new weapons will emerge in the
fight against diseases like cancer.
Some may target specific proteins in
the replication machinery, acting
likea molecular monkey wrench in
the gears.
But cancer is a tricky disease,
cautions O'Donnell. "If you tried
to inhibit the polymerase, for
example, you would also inhibit
normal cells that divide, like the
cells in the lining of the gut or those
that make blood cells," he says. "It
is important in cancer therapy to
find drugs that are much more
sophisticated, that will target only
the cancer cell." •
SEARCH
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Roderick MacKinnon

laboratory: Molecular Neurobiology and Biophysi cs
area of study: Structure and function of ion channels

ponng over
ion channels
•

T.HE MYSTERIES OF

P

rofessor Roderick MacKinnon set up his
Laboratory of Molecular Neurobiology and
Biophysics at Rockefeller with a specific goal
in mind-to obtain a high-resolution three
dimensional structure of a potassium ion channel pro
tein. He fully expected that his quest for the structure
would be a long-term undertaking, requiring at least a
few years. But less than two years after his arrival here,
MacKinnon has already accomplished his mission, as
evidenced by the image of the X-ray crystallographic
structure of an intact potassium channel protein on
the cover of the April 3, 1998 issue of Science.
MacKinnon, who was appointed an investigator
with the Howard Hughes Medical Institute last year,
modestly attributes his success to "some very lucky
breaks and extremely hard work on the part of my
entire laboratory."
Outside experts, however, are far more forthcom
ing with their praise for this achievement-"A
remarkable accomplishment," proclaimed Clay
Armstrong of the University of Pennsylvania, who -+

BY NEERAJA SAN KARAN
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reviewed MacKinnon's paper in the
same issue of Science. "It is a dream
come true for biophysicists."
Ever since their discovery in the
1950s, ion channels have been the
subject of intense interest to many
scientists because of the key role
they play in maintaining some of the
body's most vital functions. Seated
in the oily layers of the cell mem
brane that preserves the integrity of
each cell, these proteins govern the
flow of different ions such as potas
sium, sodium and calcium into and
out of cells. The proper balance
of these ions is essential for
fundamental operations such as the
transmission of nerve impulses
throughout the body and brain.
Shaped like tiny doughnuts float
ing in oil, the ion channels perform
the dual functions of gateway and
gatekeeper. The holes in the dough
nut form the gateway through which
the ions flow. However, these holes,
or pores, are endowed with special
properties that enable different
channel proteins to be selective as to
which ions they allow passage. Like
security guards who check ID before
allowing entrance, these molecular
gatekeepers only allow specific ions
to pass through their pores.
What allows the ion channel
proteins to work as they do? This is
the question that has engaged
MacKinnon for over a decade,
beginning with his observation of an
experiment monitoring the electrical
activity of a potassium channel,
when he was a medical student just
contemplating a switch to basic
science. He joined the laboratory
of his undergraduate mentor
Christopher Miller at Brandeis
University, where, as a postdoc, he
began to work on biophysical
aspects of channel function. He
chose to focus specifically on the
protein selective for potassium ions,
because it happened to be the target
•
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Ball-and-stick model of a potassium channel from the bacterium Streptomyces lividans looking down
the pore, which has a potassium ion (red sphere) positioned inside it. The protein is composed of four
identical subunits surrounding a central pore. The overall molecular architecture is expected to be
preserved in all known potassium channels.

of Miller's lab and also because, at
the time, it was the least-studied ion
channel, says MacKinnon.
Beginning with electrophysiologi
cal and biochemical approaches,
MacKinnon studied the interaction
of the potassium channel with a
specific toxin derived from scorpion
venom and deduced that the toxin
inhibited the flow of ions by sitting
directly on the pore of the channel.
This led to questions about which
specific regions of the channel
proteins bind to ions and the toxins.
Investigations along those lines
became possible after 1987, when
scientists cloned the genes for
potassium channels in fruit flies.

In the wake of this development,
MacKinnon turned to the field of
molecular biology. By systematically
mutating the channel gene at specif
ic locations and observing the
effects on the channel's ability to
bind to the specific ions, he was- able
to pinpoint ion-binding capacity to a
single region of the protein.
"All potassium channel proteins
contain a little signature stretch of
about 8 to 10 amino acids, which is
specific for the ion," explains
MacKinnon. "The sequence is
conserved across evolution from
bacteria to humans. In fact, some of
these proteins have no features in
common except for this signature.

It's as if biology chose only one way
to select for potassium ions."
Meanwhile, genetic evidence
suggested that a single potassium
channel consisted of multiple
protein subunits. MacKinnon deter
mined that a functional channel has
four identical subunits that join
together like the staves of a barrel
around the central hole. Each of the
subunits contains the ion-specific
signature sequence, "which forms a
loop extending into the center of the
hole to create a pore selective for
potassium ions," he explains.
The pore-forming loops seemed
to govern specific functions such as
ion selectivity, but without a clear

channel proteins in much larger
quantities than had been possible,"
remarks MacKinnon.
Armed with sufficient amounts of
channel protein, the scientists could
turn their attention to tackling their
other problem, namely growing good
crystals. Historically, membrane
bound proteins like ion channels
have been notoriously bad candidates
for protein crystallography, because
the detergents used to separate such
proteins from lipids-a necessary step
in making good protein c�ystals
often destroy the proteins as well.
"To give an idea of the labor
involved in determining the ideal
parameters for growing good crys-

ions, which are smaller, do not fit
properly in the cavity. "The oxygens
in the pore cannot get as close to
the sodium as they do to potassium.
Consequently sodium ions are better
stabilized by oxygens in water mole
cules and do not enter the pore,"
MacKinnon adds.
The channel structure also sug
gests an explanation for the seeming
paradox of a channel protein's ability
to reconcile high ion selectivity with
high throughput, or the rapid flow of
ions through the channel.
"The two properties seem incom
patible because high selectivity
implies that the interaction between
the channel and ion must be a

The channel structure also suggests an explanation for the seeming paradox
of a channel protein's ability to reconcile high ion selectivity with high throughput,
or the rapid flow of ions through the channel.
idea of the 3-D structure of the
channel, MacKinnon says there was
no way to test the truth of this idea.
So he came to Rockefeller where he
hoped to master crystallographic
techniques and solve the structure
of the potassium channel.
The very nature of the problem
led MacKinnon and others to antici
pate slow progress in their work. A
basic requirement for protein crystal
lography is that scientists have
sufficient quantities of the starting
material or protein, in order to grow
crystals for X-ray analysis. But
although potassium channels are
present in virtually all cells, they are
usually produced in low quantities.
Fortunately, this hurdle was over
come when a group of scientists
discovered and cloned a potassium
channel from the bacterium
Streptomyces lividans, using the very
signature sequence that MacKinnon
had discovered a few years earlier.
"The bacterial system cleared the
path by giving us a way to express

tals, we concocted a crystal screen
with a total of 900 different condi
tions at two different temperatures
and with 10 detergents," says
MacKinnon. "Luckily we hit on the
right combination relatively early."
The structure of the potassium
channel (see figure) confirms
MacKinnon's theory about the
pore-loop structure determining
ion selectivity and also offers an
explanation as to why the channel
prefers potassium over sodium ions.
"Basically the potassium selectivity
filter is a cylindrical cavity lined
by slightly charged oxygen atoms
which, in turn, are held in place by
structural elements in the portion
of the channel protein that traverses
the membrane," explains
MacKinnon.
This structure confers a certain
rigidity to the cylinder and deter
mines the diameter of the oxygen
lined pore. A charged potassium ion
fits neatly into the narrowest config
uration of this cylinder. Sodium

strong one, which would not be
conducive to letting the ions escape
past the protein into the cell,"
MacKinnon says.
But it appears as though the
selectivity pore resolves this paradox
by placing two ions near each other
where they experience mutual
repulsion by virtue of their electric
charge. "This suggests that the
strong attractive forces between
the potassium ions and channel
are counteracted locally by the
repulsive forces between two
positively charged potassium ions,
which allows each ion to fall
through at a rapid rate," he adds.
Having solved the elusive struc
ture of the channel, MacKinnon
plans to obtain information about
channel structure at still higher
resolutions and probe other aspects
of their function. Ultimately, he
says, "My aim is to figure out
how channel proteins function as
the electrical impulse generators
in biology."•
SEA�CH
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laboratory: Molecular Vertebrate Embryolo gy
area of study: formation and patterning of the vertebrate embryo

challenging
cell fate
determination

THE CONCEPT OF EMBRYONIC

hat causes cells taken from a particular
region of an early embryo to become
nerve cells in some situations and skin
cells in others? This is a question that
has puzzled embryologists throughout most of the 20th
century The answer, arrived at by Associate Professor
Ali Hemmati-Brivanlou, head of the Laboratory of
Molecular Vertebrate Embryology at The Rockefeller
University, holds the potential to yield new methods
to inhibit tumor formation, treat neurodegenerative
diseases and improve plastic surgery
As early as the 19th century, the search was on for
the answers to this intriguing puzzle. Even without the
aid of the powerful imaging technology currently avail
able, embryologists were able to draw astonishingly
accurate fate maps, detailing embryonic development
and cell migration. One such fate map showed that
cells from the dorsal, or back side, of the outermost-+
BY

URMILA RANADIVE
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layer of an early embryo were des
tined to become the nervous system,
while cells from the ventral, or front
side, would differentiate into the
epidermis, or skin.
In 1924, German embryologists
Hans Spemann and Hilda Mangold
used these potentially neural and
epidermal cells to perform experi
ments that would garner Spemann a
Nobel Prize. Spemann and Mangold
took a small number of cells from the
dorsal-equatorial region of an early
embryo and implanted them into the
ventral side of a different embryo.
What they got was an embryo with
two heads and two main body axes,
including two complete nervous sys
tems. Because the second nervous
system derived from cells that would
normally have become epidermis,
the scientists concluded the trans
planted dorsal cells were sending
signals telling the host ventral cells
to be neural. The researchers called
the transplanted signaling region an
organizer. Embryologists spent the
next 70 years trying unsuccessfully
to find the molecule that told
epidermal cells to become neural.
Following on a project that he
started during his postdoctoral
studies with Douglas Melton at
Harvard University, Hemmati
Brivanlou finally solved the problem
at Rockefeller. He realized that
Spemann and Mangold had worked
under an incorrect assumption.
Cells, even from the ventral side of
an embryo, do not become epider
mal by default. Rather, without any
external signal, cells become neural.
A decade ago three groups inde
pendently observed an interesting
phenomenon that proved key to
Hemmati-Brivanlou's research. They
found that if cells of an early embryo
are removed and grown in such a
way that they do not conta_ct each
other, they become neural tissue.
In considering these results,
•
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Eight-hour old frog embry os stained for the
expression of the neural inhibitor BMP4 (blue).
At this time, as a first step toward the establish
ment of neuronal progenitors, BMP4 is removed
from the dorsal side of the emb ryo, which is the
future side of the central nervous system.

Hemmati-Brivanlou and then-RU
Research Associate Paul Wilson
recognized that the consequence of
separating embryonic cells was the
same as that of blocking communi
cation within an intact group of
such cells. "When the cells were
dissociated or couldn't communicate
they became neural," says Hemmati
Brivanlou. "But in the embryo, where
the cells contact each other and
communicate, they can become epi
dermal. For the first time we realized
that to get epidermal cells we should
look for a negative signal, one that
told the cells not to become neural."
Hemmati-Brivanlou works with

the cells of the frog Xenopus laevis to
track embryonic development. Its
1-mm diameter egg is one of the
biggest cells in the world, making it
an ideal candidate for study. Using
Xenopus cells, Hemmati-Brivanlou
identified the bone morphogenetic
protein, BMP4, as a signal inhibiting
neural development. This molecule,
for which Hemmati-Brivanlou
received a patent, delivers two
messages simultaneously: First, it
tells the cells not to become nerve
cells, and second, it tells them to
become skin cells. Since the discov
ery of BMP4, two related neural
inhibitors, BMP2 and BMP7, have
been identified by Atsushi Suzuki, a
postdoctoral fellow in the Hemmati
Brivanlou laboratory.
But a further riddle appeared in the
form of an embryological catch-22. In
the embryo, ectodermal cells some
times become neural-even if they
remain intact and are able to trans
mit the BMP4 signal to one another.
So Hemmati-Brivanlou reasoned that
to get neural cells, you must inhibit
the neural inhibitor, BMP4.
So far, three inhibitors of neural
inhibitors have been identified. These
are called neural inducers, and all
three are secreted factors expressed
primarily in Spemann's organizer. The
Hemmati-Brivanlou lab discovered
and cloned one of the neural induc
ers, known as follistatin, for which it
also received a patent. The other two
neural inducers are noggin and
chordin. Noggin was discovered and
cloned by William Smith, together
with Richard Harland, Hemmati
Brivanlou's doctoral advisor, at the
University of California at Berkeley.
Chordin was discovered and
cloned by Yoshiki Sasai and Eddy
De Robertis of the University of
California at Los Angeles.
Noggin and chordin have been
found to bind directly to BMP4,
preventing it from getting to its recep-

Lateral view of a two-day
old frog tadpole showing a
subset of cells of the embryonic
nervous system (red).

tor on ectodermal cells. The finding
that noggin and chordin generate
neural fate by eliminating the activi
ty of BMP4 provided independent
evidence for the claim originally
forwarded by Hemmati-Brivanlou.
Follistatin's mode of action is still
under investigation.
Identifying these factors is only
the beginning. Now the Hemmati
Brivanlou lab must determine the
window of time and space in which
the ectodermal cells can respond to
these factors. BMP4, for instance,
induces ectodermal cells to become
skin cells in the early embryo. But
in adult cells, that same BMP4 is
involved in forming bone. The time
frame during which cells will
become skin in response to BMP4
has not yet been determined.
Defining the window of opportu
nity for neural inducers is even
more difficult. "How can one put a
time limit on a default fate, one that
would occur in the absence of all
other molecular factors?" Hemmati
Brivanlou asks.
Epidermal or neural induction
can occur on many levels. Factors
from outside or inside the cell may
influence transcription-the synthe
sis of RNA out of DNA-and trans
lation-the conversion of an RNA
sequence into proteins. The
Hemmati-Brivanlou laboratory aims
to understand what happens down
stream of BMP4's activity. How does
BMP4 tell a cell not to become

neural? How does it tell the cell to
instead become epiderm�l?
Scientists know that BMP4 binds
to a receptor on the surface of a cell.
The binding acts as a trigger for a
signal that gets passed from the
receptor to the nucleus. "Like
runners in a relay race," explains
Hemmati-Brivanlou, "signal
transducing proteins called SMADs
pass the signal baton along until it
reaches the nucleus."
SMADs can also work as signal
blockers. So even if BMP4 binds to
the surface of a cell, certain SMADs
can act as internal inhibitors, revers
ing the fate of the cell back to neural.
But if the epidermal inducing
signal does get transduced all the
way to the nucleus, it affects the
transcription of DNA. Inside the
nucleus, the signal turns on the
genes involved in skin formation
and turns neural genes off.
Postdoctoral Fellow Atsushi
Suzuki has identified msxl as the
first gene to get turned on when the
BMP4 signal to make epidermis
arrives at the nucleus. Another
postdoctoral fellow in Hemmati
Brivanlou's lab, Daniel Weinstein,
has identified and cloned a gene,
called eIF-4AIII, which regulates
translation of BMP4's signal. The
eIF-4AIII gene had never been
cloned before in an animal and is in
the works as another patent for the
Hemmati-Brivanlou lab.
In addition to adopting a given

fate, embryonic cells also have the
continuous task of maintaining their
identity. Maintenance can be
achieved through positive feedback
loops or by extracellular signals,
provided by neighboring cells.
Though their focus is basic
research, the Hemmati-Brivanlou
laboratory's findings have many
potential applications. Their patent
on BMP4 is essentially a patent for
epidermal induction. The ability to
create skin promises to be beneficial
for plastic surgery, burn victims and
wound healing.
The other side of the epidermal
induction coin is neural inhibition.
BMP4 is part of the TGF�, or trans
forming growth factor-beta family,
and acts as a strong neural inhibitor,
explains Hemmati-Brivanlou, "so
brain tumors or spinal tumors are
obvious targets for BMP4 treatments."
Some of the SMADs are neural
inhibitors that work downstream of
BMP4 and could be used to prevent
the growth of tumors of neural origin.
Finally, neural inducers like
follistatin, noggin and chordin
represent promising treatments for
neurodegenerative diseases like
Alzheimer's and Parkinson's, in
which the regeneration of dying
neural tissue would be beneficial.
For now, Hemmati-Brivanlou says
he will leave the applications of his
findings to other scientists and clini
cians, while he continues to focus
on basic research. •
SEARCH

iological clocks are ubiquitous in
nature, influencing everything from
a tree's tendency to shed its leaves in
autumn to a bird's decision to head
south for the winter. A master clock
ticks within each of us as well-a biological
timepiece that guides us through the daily,
24-hour circadian cycle of sleep and wakeful
ness. It is this clock that leaves us fighting jet
lag when we travel across time zones, then
forces us to sleep no matter how much work
we have left to finish. The biological clock
also maintains an indirect control over other
cyclic processes in the body, regulating,
among other things, the daily waxing and
waning of body temperatures and hormone
levels. While these daily fluctuations help us
make the transition from sleep to wake, they
also make it more likely for events such as
heart attacks or asthma attacks to occur at
certain times of the day.
Professor Michael Young, head of the
Laboratory of Genetics at The Rockefeller
University, says he has been fascinated with
nature's timekeeper since he was a junior -+
BY URM I LA RANADIVE

high school student. He earned
his B.A. in biology in 1971 and in
1975 his Ph.D. in genetics at the
University of Texas at Austin, where
he noticed new work on the genetics
of circadian rhythmicity. Several years
later, after postdoctoral work in bio
chemistry at Stanford Medical School,
he moved to RU and turned once
again to this longtime interest, setting
out to understand the molecular
underpinnings of the biological clock.
By 1984, Young had cloned a
gene named period (per) of the fruit
fly Drosophila that appeared to affect

snowshoe hares, exist in highly
synchronized, 10-year population
cycles. For example, suppose the
cycle begins when the lynx
population has hit bottom: With few
predators, the number of hares rises,
supporting an ever larger lynx popu
lation to prey on the hares. As food
supplies plummet, however, fewer
lynx survive, and once again the
hare population rebounds.
Although not an animal
behaviorist, Young observed the
interdependent interactions of the
lynx and hare populations and saw

so, how. He went into this research
armed with a few key observations.
First, the TIM protein was rhythmic.
That is, TIM followed the same
cycle as PER protein. Second,
cycling of the PER protein did not
occur in flies with a mutation of the
tim gene. The key to the puzzle lay
in a significant observation made by
Leslie Vosshall, a doctoral student in
Young's laboratory.
"Leslie's work was our first
indication that there really was a
close partnership between these two
proteins, TIM and PER," says Young.

...the per and tim partnership is so close that their daily cycling cannot occur
without their two proteins, PER and TIM, working in concert.
circadian rhythms. A homolog, or
descendant copy, of this gene has
recently been isolated in humans by
research teams at the University of
Tokyo's Institute of Medical Science
and Baylor College of Medicine.
"Based on this discovery, I'd say
it's likely that the genes, proteins
and mechanisms emerging from
Drosophila are telling us how our
own pacemakers work," says Young.
But in 1984, Young was still
struggling to understand why per
was important for rhythms. Young
knew that the gene was needed for
circadian rhythms because flies that
expressed a per mutation in their
brain's pacemaker cells had disrupted
cycles of activity and rest. Colleagues
at Brandeis University had shown that
the mutations also blocked the cyclic
synthesis of the per-coded PER pro
tein. But it was unclear how, in nor
mal flies, the gene made a product
that was produced in a cyclical, rather
than constant pattern.
In solving the puzzle, Young
recalled a phenomenon involving
biological oscillations of a very
different kind. Two animal popula
tions, lynxes and their primary prey,
•
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a model for his molecular clock.
Perhaps interdependence was the
key: Was there a gene that influenced
per, causing its levels to rhythmically
rise and fall?

L

ooking for a second gene to
work hand-in-hand with per
involved screening tens of
thousands of Drosophila for individ
uals with aberrant sleep/wake cycles.
Adult fruit flies normally hatch from
their pupal shells at dawn, so Young
was on the lookout for flies emerg
ing at any other time of day-those
that probably had a mutation in a
gene involved in the circadian
rhythm. This process led to the
identification, and eventually the
cloning, of a gene called timeless
(tim). Young's laboratory has since
uncovered tim's pivotal role in the
molecular clock. In fact, the per and
tim partnership is so close that their
daily cycling cannot occur without
their two proteins, PER and TIM,
working in concert.
But when tim was first identified,
Young had a lot of work ahead of
him. He had yet to determine
whether tim worked with per, and if

Vosshall noticed that although tim
mutants-those that did not have the
tim gene-made per RNA, she could
not detect any PER protein. However,
when she fused the PER protein to a
very stable enzyme, she detected the
fused PER protein. But it was pro
duced in a constant pattern, without
the daily fluctuations normally
found in Drosophila. More intriguing
was that in tim mutants, the fused
PER protein was produced in the
cytoplasm, but never appeared in
the nucleus. In normal Drosophila,
the PER protein cycles in and out of
the nucleus.
Based on these and other obser
vations, Young's laboratory worked
out PER and TIM's interdependent
relationship as follows: Normally,
PER and TIM proteins are at their
greatest concentration in the
nucleus of the cell shortly before
dawn. After hitting their peak
concentrations, the proteins begin to
disintegrate and leave the nucleus.
When the cell perceives the declin
ing concentration of the proteins, it
signals the per and tim genes to begin
making RNA that will produce more
proteins. Although the RNA accumu-
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DAWN
• No transcription of per or tim genes into RNA.
• Many PER/TIM protein complexes
are in nucleus. Disintegration begins.

per gene

Cell from circadian
pacemaker region
offly brain

PER/TIM
complex
cytoplasm

PER/Tl M complex

NOON
• PER/TIM protein complexes
disappearfrom nucleus.
• per and tim genes begin transcribing
RNA but. no translation occurs.

per RNA

MIDNIGHT
• As PER/TIM complexes accumulate
in nucleus, cell stops producing per
and tim RNA and blocks further accumulation of
PER/TIM complexes.
tim RNA

DUSK

Translation of tim RNA
into TlM protein

TIM protein
ILLUSTRATION BY TERESE WINSLOW

PER
protein

• Peak levels of per and tim RNA in
cytoplasm produce high levels of PER
and TIM proteins.
• Initial binding of PER and TIM proteins
begins.

Translation of per RNA
into PER protein

lates throughout the day, very little
nu_clear protein amasses during this
time. Instead, PER and TIM abrupt
ly appear in the nucleus shortly after
dusk, long after RNA levels hit their
peak. As the proteins build up
inside the nucleus, they trigger a
negative feedback loop telling the
per and tim genes to stop making
RNA. At dawn, the cycle begins
anew with the disintegration of the
accumulated proteins.
The pace of the clock is set by
the time lag between the transcrip
tion of the genes' DNA to RNA and
the subsequent nuclear appearance
of PER and TIM. Young's laboratory
has identified the key contributors
to this lag. First, the researchers
discovered that the PER and TIM
proteins must join together in the
cytoplasm in order to enter the cell's
nucleus. Their second discovery
hinged on two significant factors:
First, Vosshall observed that the
PER protein is rapidly broken down
in the cytoplasm when it is not
paired with TIM, and second, they
identified a new gene, named dou•
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The Drosophila clock protein TIMELESS accu
mulates to high levels in nuclei of the eyes and
certain cells of the brain at night (top), but is
rapidly destroyed when the fly is briefly exposed
to light (bottom).

bletime (dbt), which regulates this
process (as reported in Cell, July 10,
1998). The result is that PER pro
tein levels are actively held down,
even as RNA levels are rising.
Add to this another complicating
factor. The cytoplasm of the cell

contains factors that also compete
for the attention of PER. Newly
made PER proteins have cytoplasmic
localization domains (CLDs) that
inhibit movement to the nucleus by
holding them in the cytoplasm. It
just so happens that PER's CLD is in
the same area as its TIM binding site.
During the day, TIM is not pre
sent in high enough concentrations
to successfully compete for PER's
CLDs. This is because TIM is a
light-sensitive protein. So while
PER's CLDs hold it in the cytoplasm,
allowing the unpaired proteins to
be actively destroyed, TIM is being
removed by light.
The scenario changes at dusk,
when there is no light to destroy the
TIM protein as it is being produced
by its RNA. At this point, TIM
accumulates in large enough quantity
to capture PER before it is snatched
by the CLDs and degraded in the
cytoplasm. Thus bound, and only
after this union, can the PER/TIM
complex enter the nucleus.
"Requiring that the PER and TIM
proteins be paired before entering

the nucleus is a good way of ensur
ing a lag between the time that the
tim and per genes are transcribed to
the time that the TIM and PER
proteins can reenter the nucleus
and suppress the transcription of
their genes," explains Young. "So
we find several regulatory steps that
collaborate to give the per and tim
genes a long period during which
they are not inhibited by their
protein products."
But it is light-sensitive TIM that
determines the clock's period in a
natural environment. TIM needs
light-though not a full 12 hours
to maintain a 24-hour clock. The
interval of light, which can reset the
clock no matter where the body is in
the circadian cycle, need only be
long enough to completely degrade
TIM and allow a sufficient buildup
of RNA to restart protein production.
How do pacemaker cells detect
light? In the fly, Young thinks, pace
maker cells in the brain have their
own photoreceptors that detect
light and influence the circadian
cycle. The photoreceptor system is
more complicated in mice and
humans, who have more complex
brain structures. Pacemaker cells in
these two animals are located in the
suprachiasmic nucleus (SCN), a
conglomeration of neurons in the
brain's hypothalamus. The sleep/
wake cycle is probably controlled
by PER and TIM cycling in these
pacemaker cells, which are never
directly exposed to light. But the
proteins have also been found in
the mammalian retina, which has
its own clock. So communication
between clocks in the eyes and
brain may keep behavior in register
with the environment.
A host of unanswered questions
remain about how fluctuations of the
PER and TIM proteins in pacemaker
cells affect an animal's sleep/wake
cycle. Young reasons that the cycling

of the per and tim genes will be
echoed in the cycling of other genes
in the cell. During the last few years,
scientists have paid special attention
to clock control genes (CCGs). The
activity of these genes oscillates with
the circadian rhythm, establishing
cycles in the production of other
hormones, transcription factors and
in�racellular components. The CCGs
are influenced by, but do not them
selves affect, the rhythm of the clock.
An example of a CCG is a gene
that produces N-acetyl transferase,
an enzyme required for melatonin
synthesis. Because the transcription
of this gene cycles up and down in
concert with per and tim cycles in
the pacemaker cells, melatonin is
produced in cycles. Melatonin, a
hormone that causes drowsiness,
has a direct effect on the sleep/wake
cycle (see Melatonin Miracle, p. 23).
"We imagine that as we build a
bigger catalog of the products of
these CCGs, we'll have a pretty
good indication of the cascade of
events that can drive the whole
behavioral response to the biological
clock," says Young.

T

he biological clock regulates
more than just the
sleep/wake cycle. All kinds of
hormones are produced in rhythms,
peaking at set times during a 24hour period. The biological clock
also controls the progression of
events during a 24-hour interval,
ensuring that event A occurs before
event B, which precedes event C. In
this way, an organism can anticipate
the time of day both behaviorally
and physiologically (see Circadian
Call to Arms, this page).
Recent studies have demonstrat
ed the existence of independent
clocks throughout the body, indicat
ing that time of day is important to
all parts of the body, not just the
brain. Steve Kay at The Scripps

Research Institute, for example,
showed that leg, wing and antennae
tissue from Drosophila will continue
to rhythmically produce PER and
TIM in the absence of any input
from the fly's central nervous sys
tem. Other researchers have shown
that in eye tissue removed from
mice, the retina will continue to
secrete melatonin with a 24-hour
circadian rhythm.
"You've got cells all over the body
that find it very important to pay
attention to time of day," says
Young, "important enough to keep
track of time locally, instead of having
to depend on a central integrating
pacemaker like the one in the brain
that controls the overall sleep/wake
behavior."

of human circadian rhythms. His
research may also provide a basis for
therapies to treat afflictions that are
influenced by circadian rhythms.
Timing medical treatments to the
body's natural rhythm, for example,
could become an important new
therapeutic tool. Researchers have
found that cancer patients, for
instance, can be as much as 10 times
more sensitive to a chemotherapeu
tic drug at one time of day than they
are at another.
This sensitivity might result from
the variable concentrations of other
hormones and factors influenced by
the circadian clock. Drug regimes
are currently being created that
specify time of delivery in addition
to dosage and frequency.

Recent studies have demonstrated the existence
of independent clocks throughout the body, indicating
that time of day is important to all parts of the body,
not just the brain.
Further evidence to support the
importance of time-keeping can be
found in nature, where activities
controlled by the circadian rhythm
extend from the turning of leaves in
autumn to foraging and hibernation
patterns of animals. These seasonal
changes depend on an organism's
measuring and comparing day
length against its internal circadian
oscillator.
Noting the use of biological clocks
by nearly all organisms, scientists
think that these clocks have been
highly conserved throughout evolu
tion. For example, a counterpart to
the fruit fly's per gene has been found
in mice. And the recently discovered
homolog of the per gene in humans
is further evidence that the compo
nents of the clock are highly
conserved among species, making it
likely that Young's Drosophila research
will result in a better understanding

Preventive measures could also be
developed for asthma and heart
attacks, which occur more frequently
at specific times of the day. Treat
ments for jet lag and insomnia might
also come from Young's research.
But for now Young's interests will
take him back to the PER/TIM
protein complexes in the cell's
nucleus. "For us, there are still
important unsettled questions:
How much of the Drosophila clock
system is conserved in human pace
maker cells? How is the rate of the
molecular cycle regulated with an
accuracy of minutes? Can our
discovery of the molecules forming
this clock take us directly to the
genes that affect behavior in a time
dependent fashion?" Young is stick
ing to fruit flies, looking to identify
and understand the function of the
remaining components of the
molecular clock. •
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1:00 a.m.
• Pregnant women are most likely
to go into labor.
• Lymphocytes are at their peak.
2:00 a.m.
• Growth hormone levels are highest.
4:00 a.m.
• Asthma attacks are most likely.
6:00 a.m.
• Onset of menstruation is most likely.
• Plasma insulin is lowest.
• Blood pressure and heart rate begin to
rise rapidly.
• Cortisol (stress hormone) levels begin
to rise.
• Melatonin levels begin to fall.
7:00 a.m.
• Symptoms of allergic rhinitis (hay fever)
are worst.
8:00 a.m.
• Calories are burned most readily.
• Risk for heart attack and stroke is
highest.
• Symptoms for rheumatoid arthritis
are worst.
• Lymphocytes are at their lowest
daytime level.

noon

• Level of hemoglobin in blood peaks.

3p.m.
• Grip strength, respiratory rate and
reflex sensitivity highest; good time
for athletes.
4p.m.
• Body temperatures, pulse and blood
pressure peak.
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6p.m.
• Urinary flow is highest.
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9p.m.
• Pain threshold is lowest.
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11p.m.
• Skin is most reactive; allergic response
most likely.
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of an infecting virus. Hanafusa
presented the following problem to
Kuriyan: How did mutations in this
single gene change the functioning
of its protein product to induce a
cell to start developing tumors?
Kuriyan, now Patrick E. and
Beatrice M. Haggerty Professor, head
of the Laboratory of Molecular
Biophysics and a Howard Hughes
Medical Institute investigator, has a
vivid memory of Hanafusa introduc
ing him to the Src problem by draw
ing a straight line on the blackboard
and blocking out different regions,
representing different parts of the
molecule. Based on biochemical and
genetic analyses, Hanafusa knew

Increasing
the Magnification
of Discovery
Technology led the way to
discovery of the src gene.
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about mutations in different parts of
the src gene that resulted in the
"transformation" of normal cells to
cancerous types, but he did not have
a precise picture of how these muta
tions altered the normal activity of
the Src protein.
One of the most significant
breakthroughs toward answering
this question came last year, when
Kuriyan's group, as well as Stephen
Harrison's laboratory at Harvard
University, solved the crystal struc
tures of two Src proteins. The
achievement represents an impor
tant milestone, not only with respect
to answering specific questions
about Src activity, but also because

of Src's leading role in the history of
understanding the general mecha
nisms underlying cancer. It is a story
with deep roots at Rockefeller, datip.g
back to the turn of the century
when Peyton Rous discovered the
first tumor-inducing virus, thereby
providing future cancer researchers
with an indispensable tool for prob
ing cell behavior and its breakdown.
Rous came to RU-then the newly
founded Rockefeller Institute for
Medical Research-in 1909 on the
invitation of the first director, Simon
Flexner, to head a laboratory for
cancer research. Within a few weeks
of his arrival, a chicken breeder
brnught a chicken to Rous's labora
tory. The bird had a large growth
that he recognized as a sarcoma
tumor. Knowing that fowl tumors
had not yet been studied in any detail,
Rous began a thorough analysis of
its properties and pathologic effects.
Rous found that the tumors were
transplantable over several genera
tions and began to search for a
causative agent within the tumor
cells. Using new freeze-drying tech
niques developed by his colleague,
James Murphy, Rous broke open the
tumor cells, filtered the contents to
ensure the complete removal of
intact cells and injected this cell-free
material into chickens to see
whether they developed sarcomas.
In a now classic paper entitled "A
Sarcoma of the Fowl Transmissible
by an Agent Separable from the
Tumor Cells," published in The
]ournal of Experimental Medicine in
1911, Rous described the tumor
agent for the first time and speculat-

Peyton Rous

James Murphy

Discovers tumor
agent, later called
Rous Sarcoma Virus
(RSV), that can
transmit cancer in
chickens.

Proposes that RSV
is a transmissible
mutagen.

"The first tendency will be to regard the self-perpetuating agent active in this
sarcoma of fowl as a minute parasitic organism."
-PEYTON ROUS, THEjOURNAL OF EXPERIMENTAL MEDICINE,

ed on its identity.
"The first tendency will be to
regard the self-perpetuating agent
active in this sarcoma of fowl as a
minute parasitic organism," he
wrote, hinting at the possibility that
the tumor agent was a virus. In
1966 Rous received a Nobel Prize for
his discovery of the Rous Sarcoma
Virus (RSV). Within the scientific
community, however, there appears
to have been little early acceptance
for the idea that a virus could cause
cancer. In 1931 Murphy published a
paper in which he proposed that the
tumor-inducing agent was perhaps a
"transmissible mutagen," whose
mode of activity was to induce per
manent mutations in the host cells
that resulted in cancer.
Photograph ofa chicken (c.

1911)

As is turned out, the two ideas
were not mutually exclusive.
Murphy's idea that mutations led to
cancer was indeed correct. RSV, as
scientists learned, served as one of
the vehicles that introduced specific
tumor-inducing mutations into the
cell. Other mutagens s�ch as chemi
cals and radiation could also cause
mutations that initiated cancer. But
neither of these agents produced
consistent results with respect to the
type of tumor that was formed. So,
for a new generation of scientists,
RSV served as the main vehicle for
the molecular analysis of cancer.
As tumor virologist Harry Rubin
remarked in 1966, " ... what else if not
tumor virology can lead to an under
standing of the molecular basis for

in which Rous induced a tumor using a filtered cell extract containing RSV
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Harry Rubin
and Howard Temin (Caltech)
Develop an assay for RSV in tissue
culture which opens up genetic and
biochemical analysis of tumor viruses

Identification of src gene as
tumor-inducing component
of RSV.
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the malignant behavior of cells?"
In 1958 Rubin and Howard
Temin at the California Institute of
Technology in Pasadena developed a
method to assay RSV in tissue cul
ture. This gave scientists a quantita
tive handle on the virus and allowed
them to monitor changes induced
by the virus directly at the cellular
level, rather than having to inject a
whole animal and wait for tumors to
develop. It enabled scientists to map
out the entire RSV genome and
assign specific functions to specific
genes. As a postdoc in Rubin's
laboratory at the University of
California, Berkeley, during the early
1960s, Hanafusa was an active par
ticipant in the analysis of mutants
deficient in their ability to cause
transformation-which eventually
led to the identification of src as the
single gene required for inducing
cellular transformation.
At the outset, the discovery of src
opened up more questions than it
answered. How did it induce trans
formation? The gene was obviously
not required for either viral replica
tion or survival--so why did it exist
at all? What function did the gene
and its protein product serve?
In 1976 Michael Bishop and
Harold Varmus at UC, San Francisco,
found that a version of the viral src
(called v-src) gene was present in
normal uninfected cells. Hard on the

D. Stehelin, M. Bishop
and H. Varmus (UCSF)
Discover that a version of src exists
in the DNA of normal, uninfected cells.
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" ...what else if not tumor virology can lead to an understanding of the molecular
basis for the malignant behavior of Gells?"
1966
-HARRY RUBIN, TUMOR VIROLOGIST,

heels of this discovery, Hanafusa,
who had moved to Rockefeller in
1973, furnished the genetic evidence
that cellular src (c-src) sequences
did in fact substitute for the trans
formation function missing in defec
tive RSV mutants. To achieve this,
he injected uninfected chickens with
mutants of RSV that were known to
have lost most of the DNA from
their src gene and looked for the
development of tumors.
"My prediction was that viruses
containing partial deletions of the
src sequence would undergo recom
bination with cellular sequences at a

tumor tissue, Hanafusa found he
could recover viruses with complete
src genes that were evidently derived
from the host cell and not from the
original sarcoma virus.
The discovery of c-src and v-src
played a major part in reconciling
the seemingly disparate theories of
the viral and mutational origins of
cancer in the following manner: The
normal cell contains a gene with the
potential for inducing cancer, but
this gene-the protooncogene-can
cause transformation only after it
was mutated to form an oncogene.
All known cancers can be traced

A schematic representation of the Src protein highlighting its principle domains and tyrosine phospho
rylation sites. The green segments correspond to the protein fragment structure pictured on page 31.

higher rate and thus be able to
produce tumors," explains
Hanafusa, who is now Leon Hess
Professor and head of the Jeanette
Warren Davidson Laboratory of
Molecular Oncology.
Sure enough, the chickens inject
ed with these mutants developed
tumors that differed from the
original sarcomas in two major
respects: They appeared two months
rather than a week after the injec
tions and developed very far away
from the site of inoculation of the
virus. Upon examining the new

Hidesaburo Hanafusa (at Rockefeller)
Finds that non-tumorigenic RSV can
become tumorigenic after picking up
cellular src DNA.
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to mutations in some normal
protooncogene.
Once scientists discovered the
existence of cellular and viral src
genes (and proteins), they naturally
turned their attention to investigating
the differences in the two forms that
caused such a drastic change in their
transformation capabilities. By 1987,
Hanafusa and others had conducted a
systematic comparison of the DNA
and protein sequences of cellular and
viral src and identified the major dif
ferences. They pinpointed the critical
difference to a single amino acid in

Analysis of the differences
between cellular and viral src
DNA and protein sequences.

the tail region of the protein-a tyro
sine present at position 527 of c-Src
and missing from v-Src.
But even this discovery failed to
answer the crucial question of how
the absence of a single amino acid
changed the protein to a form that
induced cellular transformation?
Investigators looking into functional
aspects of src had determined that
the normal gene encoded a key
component of the network of molec
ular signals that regulate growth and
development patterns of a cell. Src
functions as a kinase-a protein that
transfers phosphate molecules to
other cellular proteins and activates
them-ultimately sending a message
to the cell to start dividing. Kinases
must be very tightly regulated or else
cell division can run amok, resulting
in cancer. In c-Src this regulation was
found to be linked directly to Tyrosine
527: When this amino acid was
phosphorylated, the protein appeared
inhibited, while removal of the phos
phate from this site resulted in an
elevated activity.
This observation immediately
suggested that v-Src induced trans
formation by permanently removing
the internal brake from the cellular
protein. Hanafusa o�tained further
evidence in support of this idea
when he discovered a portion of the
molecule called SH2 near the head of
the Src protein, which has a special
affinity for binding with phosphory-

Identification of regulatory regions
(SH2 and SH3) in oncogenes
Hanafusa proposes model for Src
regulation by interactions within protein.

"The whole enzyme appears to be functioning like a Rube Goldberg machine,
employing many complex parts to perform a simple task."
-JOHN KURIYAN

lated tyrosine 111olecules. The discov
ery had two exciting implications.
First, it suggested that the SH2
region could bind to the phosphory
lated Tyrosine 527, like a snake
biting its own tail. An intramolecu
lar contortion of this kind, Hanafusa
imagined, would block Src's active
site-its kinase domain-and thus
prevent it from phosphorylating
other proteins. The finding also
indicated that the SH2 domain
played the role of a molecular
postman, who recognized specific
intracellular addresses-the tyro
sines-where the kinase delivered
the phosphate molecules. When
attached to the internal tyrosine, the
postman could no longer reach the
other addresses, which resulted in
the suppression of Src activity.
This then was the model that
Hanafusa presented to Kuriyan in
1989: A linear diagram of the Src
protein with its component domains
and the position of the key muta
tions, superimposed with biochemi
cal information on the possible areas
of interaction.
"The question that Saburo posed,
very simply and directly, was 'How
is Src regulated? "' recounts Kuriyan.
"To proceed any further with under
standing how it worked, one needed
to know what it looked like in three
dimensions."
The researchers had their first
breakthrough when Kuriyan and his

Collaboration of several Rockefeller
laboratories. Determination of the
3-D crystal structure of SH2 region
of Src.

Three-dimensional crystal structure of the Srcfamily kinase Hck. The molecule is seen here in its
inhibited form with the phosphotyrosine at position 527 bound to the SH2 domain. SH3 and kinase
domains are also identified.

collaborators s�lved the crystal
structure of a v-Src SH2 domain in
1992. The structure immediately
clarified the way in which SH2
domains could recognize phospho
tyrosine molecules and provided the
first bit of support for Hanafusa's
proposed mechanism of control.
Then last year, Kuriyan, along
with postdocs Ismail Moarefi and
Frank Sicheri, published the com
plete crystal structure of Hck-a
Src-related molecule found in white
blood cells-showing how the
unmutated molecule looks in its
regulated state. In the broadest

John Kuriyan lab
Determination of 3-D crystal
structure of Src-family protein Hck.

sense, the structure confirms the
validity of Hanafusa's conjectures
that the Tyrosine 527 plays a key
role in regulation by binding with
SH2. In addition the structure
reveals other, subtler details about
interactions within the Src molecule,
which contribute to the integrity of
the overall structure.
"The whole enzyme appears to be
functioning like a Rube Goldberg
machine, employing many complex
parts to perform a simple task,"
explains Kuriyan.
What next? "While our under
standing of individual components
such as Src and Hck is now quite
advanced, there are hundreds of
such proteins that are communicat
ing with each other to regulate cell
behavior," says Kuriyan. "The big
challenges ahead lie in understand
ing how the cells integrate and sort
through this multiparty system of
communication." •
SEARCH
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Study shows
estrogen may prevent
onset of Alzheimer's
BY LJ RM I LA RANADIVE

A

lzheimer's disease, the devas
tating illness that leads an esti
mated 4,000,000 Americans
through progressive and irreversible
declines in mental function, occurs
in postmenopausal women at a two
fold higher incidence than in males
of the same age. During the last few
years, retrospective epidemiological
studies have shown that a history of
estrogen replacement therapy in
women after menopause was associ
ated with a reduction, by about 50
percent, in the risk of developing
Alzheimer's.
Alzheimer's disease is character
ized by the buildup of plaques,
which are primarily made up of
p amyloid proteins, in the brain.
These p amyloid plaques are widely
regarded as the key to the disease.
Cortical neurons that were treated with estrogen (above) produced less plaqueforming, � amyloid
protein than neurons that were not exposed to the hormone.

In a study published in the April
1998 issue of Nature Medicine, a
research group led by RU Professor
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Paul Greengard, along with members
of RU Professor Brian Chait's labora
tory and researchers at other institu
tions, demonstrated that exposure to
estrogen correlates with a decrease in
p amyloid protein production.
In making the link between
estrogen and P amyloid, the
Greengard lab's study provides the
first molecular basis for understand
ing why estrogen therapy works. It
also supports the continued use of

estrogen replacement therapy, which
is already widely employed to treat
and prevent osteoporosis in post
menopausal women and which has
also been found to protect healthy,
older women against heart attacks.
Greengard's study also showed
that estrogen need only be replaced
at premenopausal levels and that the
longer a woman is treated with the
hormone, the greater the degree of
protection against Alzheimer's disease.

Immature dendritic
cells (far left)
engulfing influenza
infected monocytes
(middle).

1 7P-estradiol, the form of
estrogen used by Greengard and his
colleagues in this study, is one of a
family of molecules that includes
the male sex hormones. In fact,
testosterone is a precursor of
estrogen and is the major source of
estrogen in men.
Greengard and his colleagues
plan to test other compounds,
including testosterone and estrogen
analogs, for their effectiveness,
since estrogen therapy itself has
been associated with increased risk
of developing blood clots and cer
tain types of cancer.
Now that the researchers have
established that estrogen reduces
the production of p amyloid, the
next step is to understand how.
The Greengard laboratory's strat
egy is to look inside the cell to see
where the p amyloid forms-before
and after treatment with estrogen
to see where estrogen might inter
cede in the metabolic pathways.
"If we are successful in elucidat
ing the intracellular p amyloid
production location and the molec
ular apparatus that is responsible
for the reduction of the P amyloid,
this will provide new targets for
drugs that will be effective in
treating the disease," says
Greengard, who directs the univer
sity's Zachary and Elizabeth M.
Fisher Center for Research on
Alzheimer's Disease.
Funding sources for this research
included the National Institutes of
Health, the Alzheimer� Association
and the Fisher Foundation.

Rockefeller researchers develop method to fight
tumors using dendritic cells
BY JosEPH BONNER

D

endritic cells patrol the body's
borders, guarding against
outside invaders by capturing,
processing and presenting antigens
to the body's T cells. Dendritic cells
also capture mutated pieces of the
body's own tissue from tumors as
well as normal self-tissue. Most
importantly, they are able to initiate
immune responses to either fight or
tolerate these molecules.

These findings-published in the
March 5 Nature by Bhardwaj and
her coauthors, Biomedical Fellow
Matthew Albert and Postdoctoral
Fellow Birthe Sauter-widen the
possibility of using dendritic cells to
treat human tumors, viruses and
infections.
Using the influenza virus as a
model system-because the flu
vaccine induces only antibodies and

Assistant Professor Nina Bhardwaj (left) has been working with Biomedical Fellow Matthew Albert and
Postdoctoral Fellow Birthe Sauter to harness the dendritic cell's antigen-presenting ability to fight tumors.

Recently, a team of researchers
from the Laboratory of Cellular
Physiology and Immunology, led by
Assistant Professor Nina Bhardwaj,
found a new way to harness the
dendritic cell's antigen-presenting
abifity to fight human tumors.

not killer T cells-the researchers
found they could take dendritic
cells, infect them with influenza
virus and elicit killer T cells in
culture very efficiently from normal
individuals. The cytolytic killer T
cell, also known as the CDS+ cell,
SEARCH
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plays a key role in eradicating
viruses, such as HIV, and in tumor
immunity. Autoreactive killer cells
(cells capable of recognizing the
body's own cells or antigens) must
in turn be tolerized, or turned off,
to prevent autoimmune disease.
During the course of these stud
ies, the researchers found that if
they took other antigen-presenting
cells, like macrophages, and infect
ed them with influenza, the cells
die from the infection.
In fact, the cells undergo a
process called apoptosis, a type of
cell suicide or programmed death.
Because they die in culture, the
apoptotic cells do not get a chance
to efficiently present antigens to
T cells.
Further experiments showed that
an influenza-infected apoptotic
macrophage, cocultured with an
uninfected dendritic cell and T cells
from someone who had been previ
ously exposed to influenza, allowed
the dendritic cell to acquire the
influenza antigens and trigger killer
T cells.
"Our hope is to be able to take
blood donations from a patient and
grow dendritic cells from precursor
cells in the blood," says Albert.
"We can then charge or pulse the
dendritic cells with apoptotic cells
and reinject them into the patient to
induce activated T cells.
"The discovery of this new path
way," he continues, "allows the den
dritic cell's natural machinery to
decide which pieces of the protein
are useful to an individual's immune
system."
Funding for this work was
provided in part by the National
Institute of Allergy and Infectious
Diseases, part of the federal govern
ment� National Institutes of Health
(NIH), and by the NIH Medical
Scientist Training Program.
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THE HYDROGENOSOME AT 25:

New hypothesis points to organelle's role in
evolution of eukaryotic cells

A

new hypothesis coauthored by
Associate Professor Miklos
Muller and published in the
March 5 Nature may change the way
evolutionary biologists look at the
origins of eukaryotic cells.
The classic theory of eukaryotic
evolution contends that eukaryotes
descended from proto-eukaryotes,
single-celled organisms that already
possessed a nucleus to hold their
genetic endowment. These ancestral
organisms contained inner mem
branes and a cytoskeleton that
enabled them to eat and digest
other anaerobic prokaryotes, but
contained no mitochondria.
Sometimes the engulfed bacteria
was assimilated and became an
endosymbiont-an internal partner
in a mutually beneficial relation
ship-assisting the host in respira
tion and receiving nourishment
and physical protection in return.
The endosymbiont became the
mitochondrion, the cell's energy
producing powerhouse.
With their "hydrogen hypothe
sis," Muller and his coauthor,
William Martin, a plant biologist
from the Institute for Genetics at
the Technical University in
Braunschweig, Germany, suggest
that eukaryotes arose through the
need to share the machinery of
energy metabolism for survival and
not by an evolutionary roll of the
dice. According to Muller and
Martin, the first host was a
methanogen, a single-celled organ
ism that produces methane by
consuming hydrogen and carbon
dioxide. The endosymbiont derived
from a bacterium that produced
hydrogen as waste, an ancestor of
the mitochondrion and a cell
organelle called the hydrogenosome.

Hydrogenosomes, discovered at
Rockefeller in 1973 by Muller and
Donald Lindmark, are found in
single-celled organisms that lack
mitochondria, so-called amitochon
driates. Living free or in multicellu
lar hosts, these microscopic entities
live in inhospitable environments
digestive and urinary tracts, mud,
sulfur springs-and produce hydro
gen as waste.

An electron micrograph of a cell taken from a
parasite called a trichomonad reveals an
organelle called the hydrogenosome (arrows).

The researchers suggest that the
methanogen and the bacterium that
provided its "fuel of life" met in a
hydrogen-rich environment. The
pair, separated from the hydrogen
source by an unknown means,
survived by gradually integrating
and becoming structurally and func
tionally dependent on each other.
"The future symbiont possessed
hydrogenosomal function and the
host used the hydrogen and carbon
dioxide produced by it," explains
Muller. "This is the link that forged
integration."
Funding for this work was provid
ed by the National Institutes of
Health.-). B.

RU researchers elucidate
stress response in
plants
BY MARGUERITE LAMB

H

ow do plants respond to
stresses brought on by
drought? Last December,
Nam-Hai Chua, Andrew W Mellon
Professor and head of RU's
Laboratory of Plant Molecular
Biology, and members of his labora
tory announced in the journal
Science that they had come one
step closer to elucidating this
vital process, having uncovered an
important piece of the plant stress
response puzzle.
Scientists have long known that
a plant's ability to endure environ
mental challenges depends on
stress hormones such as abscisic
acid (ABA), which signals the
release of intracellular calcium, in
turn activating a variety of stress
response genes.
Usually, a number of molecules
including receptors, proteins and

iments, postdoctoral fellow Yan Wu,
along with her coauthors and fellow
Chua lab postdocs Randy Foster and
Eric Man�chal, demonstrated cADPR's
role in ABA signal transduction.
The researchers began by inject
ing the stems of tomato seedlings
with either of two ABA-sensitive

Next, to show that cADPR is pre
sent and active in plants, Man�chal,
along with coauthor and former
postdoctoral fellow Jennifer Kuzma,
attached one of the stress-response
genes to Iuciferase, the gene that
makes fireflies glow, and transferred
this gene into a tiny plant called

Scientists have long known that a plant's ability to endure environmental challenges depends
on stress hormones such as abscisic acid, which signals the release of intracellular calcium
and activates a variety of stress-response genes.
messengers-will fill key positions
along the signal-transduction
pathway, passing the message one
to the next. But until recently, the
molecular bucket brigade linking
ABA to calcium to ABA-responsive
stress genes had remained largely a
mystery.
That mystery began to be unrav
eled last winter, when Chua and
his RU team reported that it had
definitively-and for the very first
time-located a second messenger
molecule called cyclic ADP-ribose
(cADPR) in the ABA signaling
pathway.
Through a series of tomato exper-

stress genes. They used a third,
light-activated gene as a control.
Prior to injection, all three genes
had been attached to a reporter
gene, which gives off a telltale blue
hue when activated with a substrate,
allowing researchers to monitor its
activity, as well as the activity of the
genes to which it is linked.
The researchers demonstrated
that ABA and cADPR, introduced
individually into the altered plants,
can induce expression of the stress
responsive genes. Yet inhibitors of
either cADPR or calcium will stop
stress-gene expression, even in the
presence of ABA.

Arabidopsis thaliana. The
researchers then introduced ABA
and monitored the plant's tissue for
a revealing glow.
Gene expression peaked after
four to eight hours of exposure to
ABA. And, as the researchers had
suspected, activation of this gene
was preceded by a rise in the levels
of cADPR, manifested by a rush of
calcium ions.
The team's findings hint at
intriguing possibilities for the world
of agriculture and beyond, since
cADPR is believed to be an active
messenger in a variety of cell
systems, including those of humans.
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Glucose metabolism defect identified in rare form
of Type 2 diabetes

I

n December 1996, Assistant
Professor Markus Stoffel, in
collaboration with researchers
at the Howard Hughes Medical
Institute at the University of
Chicago and the University of
Michigan Medical Center, mapped
MODYl, a particularly rare but
severe form of Type 2 diabetes, to a
gene called HNF4a. Less than a year
later, Stoffel and a colleague in the
Laboratory of Molecular Cell
Biology identified the mechanism of
this defect, which impairs the path
way that breaks down blood sugar
and provides the main signal for

the hormone that promotes absorp
tion of glucose and other nutrients by
cells. When glucose increases in the
bloodstream-for example, after eat
ing-a molecule in the� cell called
the glucose transporter-2 takes up the
sugar. T he pancreatic� cells then
sense the glucose concentration,
break glucose down and provide a
signal for insulin production and
secretion. As glucose increases in the
blood, insulin secretion increases.
T here are two major forms of dia
betes. Type 1 diabetes occurs when
the body's immune system destroys
� cells. Type 2 diabetes, the more

insulin secretion in the pancreas.
T his work, reported in the Nov. 25,
1997 Proceedings of the National
Academy of Sciences, provides the
first insight into the molecular mech
anism of this disease and opens new
avenues for developing better thera
pies to treat more common forms of
late-onset diabetes.
Diabetes affects the way sugar is
taken up and metabolized by cells. In
the pancreas, � cells secrete insulin,

common type accounting for more
than 90 percent of cases, is caused
by ineffective insulin secretion or
improper insulin action on target
tissues such as muscle, leading to
impaired glucose uptake from the
blood and increased levels of blood
glucose.
Genes are some of the most
important risk factors for Type 2
diabetes, although environment also
plays a role in the disease. Most

'
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common forms of diabetes are poly
genic, meaning that more than one
gene is involved in the disease, mak
ing it difficult to identify the genes
responsible. But in about 1 to 3 per
cent of cases, inheritance follows a
classic autosomal dominant pattern:
Anyone in a family who has one
copy of the defective gene is likely
io develop hyperglycemia, or
increased levels of blood glucose.
Known as maturity onset-diabetes of
the young (MODY), this form of
diabetes usually develops before age
25. Scientists have found four dia
betes genes, each linked to a differ
ent form of MODY.
In the new study, Stoffel and co
author Stephen A. Duncan, formerly
an assistant professor in Professor
James E. Darnell Jr.'s laboratory,
showed that the defect in HNF4a
that causes MODYl is a loss of
function mutation, meaning that the
disease develops due to the inactiva
tion of this gene.
"We have also shown that there
is gene-dosage effect-if the gene's
activity is decreased, there is a cor
responding reduction in a related
transcription factor called HNFla,
which is important for insulin
production," explains Stoffel.
Both HNFla and HNF4a belong
to a class of proteins called tran
scription factors, molecules that
switch other genes on or off. In the
early 1990s, Darnell's laboratory
identified HNF4 and showed that it
regulates gene expression in the
liver, kidney and intestine.
Stoffel and Duncan developed a
novel technique to study the effect
of HNF4a on glucose transport and
metabolism. Using embryonic stem
(ES) cells-cells found in early
stages of the embryo that can theo
retically turn into any tissue in the
body-the researchers produced
clumps of about 2,000 cells that
contain the visceral endoderm and

later develop into the yolk sac.
Genes that are expressed in the
liver, like HNF4a, are also
expressed in the visceral endoderm.
The yolk sac, which is the main tis
sue that produces insulin during
development, acts like a gut, pro
viding nutrients to the embryo.
This feature makes the visceral
endoderm a good model to study
pancreatic � cells, explains Duncan.
"The visceral endoderm provides
a physiological system for the
genetic dissection of metabolic
pathways," says Stoffel.

Most common forms of
diabetes are polygenic, mean
ing that more than one gene
is involved in the disease,
making it difficult to identify
the genes responsible.
When HNF4 was removed from
the visceral endoderm, the scientists
found a decrease in activity of sev
eral genes that act at different stages
of the insulin-secretion signaling
and insulin-production pathway.
These new findings suggest that
drugs designed to target HNF4a
activity could lead to improved
treatments for Type 2 diabetes.
"Activating HNF4a would lead
to an increased expression of the
glucose transporter-2 and the
enzymes of glucose metabolism,
increasing the rate of glucose
metabolism and increasing insulin
production and secretion," says
Stoffel.
Stoffel is an Irma Hirschl Scholar, a
Pew Scholar and Robert and Harriet
Heilbrunn Professor. Duncan is a
Naomi Judd American Liver Scholar
and an Alexandrine and Alexander
Sinsheimer Scholar. This work was
supported by the American Diabetes
Association. -J.B.

New research challenges 30 years of dogma
on treating lupus and other autoimmune diseases

F

or the more than 500,000
Americans with systemic lupus
erythematosus, the only thera
pies for this devastating autoimmune
disease are ineffective and nonspecific
antiinflammatory and immune-sys
tem suppressing drugs. But research
from the laboratory of Professor
Jeffrey V Ravetch, reported in the
Feb. 13 Science, overturns a 30-year
old dogma and may change the way
doctors treat patients with lupus.
The disease causes severe inflam
mation and kidney disease. Lupus
develops when the immune system
attacks the body's own tissues by
producing autoantibodies directed
against its own cells. The new
research identifies a critical link
between autoantibodies and inflam
mation and suggests novel ways of
uncoupling this connection.
"These studies show that pre
venting the activation of antibody
receptors by autoantibodies is an
effective way to treat autoimmune
diseases like lupus," says Ravetch,
who is the Theresa and Eugene M.
Lang Professor and head of the
Leonard Wagner Laboratory of
Molecular Genetics and Immunology.
The traditional dogma on how
autoantibodies caused disease in
lupus is based on a component of
the immune system called the com
plement system, which scientists
thought triggered inflammation.
But research from the Ravetch lab
and elsewhere during the last few
years has pointed to an alternative
pathway in which scientists think
that Fe receptors, antibody-binding
molecules that are crucial to both
triggering an immune response and
to turning off the response once the
threat has been eliminated, play an
important role.
In the new research, Ravetch and

his coauthors, Research Associate
Raphael Clynes and graduate
researcher Calin Dumitru, bred Fe
receptor-deficient mice to a strain of
mice that spontaneously develop a
disease closely matching human
lupus. The researchers found that
82 percent of mice without the Fe
receptor were alive after nine
months, as compared to less than 20
percent of lupus mice with an intact c.
Fe receptor.
Ravetch and his colleagues found
evidence of immune complexes and
a complement protein called C3 in
the kidneys of both strains of mice,
but the Fe receptor-deficient mice
showed no evidence of inflammato
ry disease.
"These results indicate that Fe
gamma receptors are required for
the initiation of the inflammatory
cascade and complement activation
is not sufficient," says Ravetch.
"These findings argue for the devel
opment of new therapeutic strate
gies for the treatment of lupus based
on blocking Fe receptors."
This work was supported by the
National Institute of Allergy and
Infectious Diseases and the National
Institute of Diabetes and Digestive
and Kidney Diseases, both part of the
federal governments National
Institutes of Health. -J. B;
SEARCH
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Mutated gene causes death of nerves in brain
BY MARION E. GLICK

A

gene responsible for the
degeneration and death of
certain nerve cells in the brain
has been cloned by investigators
from the laboratory of RU Professor
Nathaniel Heintz and The Johns
Hopkins School of Medicine.
The gene carries instructions to
make a receptor for neurotransmit
ters, which nerve cells use to
communicate, and its isolation may
be useful for further studies of such
diseases as Alzheimer's and Parkin
son's. The discovery, resulting from
mouse studies, marks the first time
scientists have identified and directly
linked a mutant gene in the gluta
mate receptor family to the death of
brain cells. Because of the mutation,
the resulting faulty receptor acts as if
a neurotransmitter always is
present-even when none of the
chemical is there. This false detection
causes the nerve cells to die.
"The mutations in the 82 gluta
mate receptor gene may play a role
in changing the metabolism of the
adult nerve cells to reactivate a
program of cell death that normally
occurs only during natal develop
ment. If we can reveal more about
this process and understand it, it
may be possible to slow down or
stop the process and preserve the
neuron," explains Heintz, head of
the Laboratory of Molecular Biology
and an investigator at the Howard
Hughes Medical Institute.
During fetal development, pro
grammed cell death is used to sculpt
the final number of cells in the
mature brain. About twice as many
cells begin the process of developing
into neurons than are needed in an
adult brain. Consequently, many of
the cells activate a biochemical
program to commit suicide, known
as an apoptotic death, because they
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Support
University launches
center for immunology
studies

I

receive certain chemical signals.
"We think that the surveillance
mechanisms that monitor the
normal metabolism of neurons are
much like those monitoring the
cell-division cycle in other types of
cells," says Heintz. "In neurodegen
erative diseases, these mechanisms
may activate the apoptotic cell death
pathway as a normal response to the
severe dysfunction of neurons. Our
discovery of the 82 glutamate recep
tor gene mutation helps us to
understand how this gene functions
in normal neurons, but the $64,000
question remains: 'How does its
altered function trigger cell death? "'
The study appeared in the Aug. 21,
1997 Nature.
The Howard Hughes Medical
Institute and the National Institute of
General Medical Sciences, part of the
federal government� National Institutes
of Health, fundefl this research, with
support from the National Institute of
Mental Health, the McKnight
Foundation, the Derelbiss Fund and the
National Alliance for Research on
Schizophrenia and Depression.

n January, the university
launched the Christopher H.
Browne Center for Immunology
and Immune Diseases. "This
center will allow us to create an
integrated program that capital
izes on the talents of a diverse
group of investigators, using the
newest scientific methods to
study the immune system's
complexities in ever-increasing
detail," says Torsten N. Wiesel,
M.D., president of the university.
"We are enormously grateful to
Chris Browne for helping us to
launch an initiative that will
have a major impact on this vital
area of biomedicine."
The new center will be direct
ed by Ralph M. Steinman, M.D.,
Henry G. Kunkel Professor and
head of the Laboratory of Cellular
Physiology and Immunology.
Other members of the center
include Michel C. Nussenzweig,
M.D., Ph.D., professor and head
of the Laboratory of Molecular
Immunology and an associate
investigator with the Howard
Hughes Medical Institute
(HHMI); Jeffrey V Ravetch, M.D.,
Ph.D., Theresa and Eugene M.
Lang Professor and head of the
Leonard Wagner Laboratory of
Molecular Genetics and
Immunology; Yongwon Choi,
associate professor, head of the
Laboratory of Immunology and
an assistant investigator with
HHMI; and David D. Ho, M.D.;
professor at Rockefeller and

Kreek lab receives
$12.3 million grant
from NIDA

T

scientific director of the Aaron
Diamond AIDS Research Center
(ADARC) for the City of New York.
ADARC affiliated with the university
in 1996.
Plans for the Christopher H.
Browne Center include creation of

to promote new clinical research on
an expanded range of immune
related conditions, particularly
autoimmune diseases and cancer,
with the ultimate goal of developing
more effective therapies. The
Rockefeller University Hospital, the

"This center will allow us to create an integrated program that
capitalizes on the talents of a diverse group of investigators,
using the newest scientific methods to study the immune
system's complexities in ever-increasing detail."
new laboratories at Rockefeller
focusing on key areas of immunolo
gy research. Scientists working in the
center will also have access to
essential core resources, including a
facility to study genetically altered
mouse models that can advance
understanding of gene function and
disease states. Other shared resources
will house state-of-the-art instru
ments for cell and tissue analysis.
A principal goal of the center is

largest clinical research center
supported by the U.S. National
Institutes of Health, will play a
major role in this endeavor.
Currently, more than 25 clinical
protocols focusing on immunology
are under way at the hospital,
including studies of the drug
thalidomide, which has proven
effective in alleviating the wasting
associated with AIDS and
tuberculosis. -J.B.

he National Institute on Drug
Abuse (NIDA) at NIH has
awarded $12.3 million to The
Rockefeller University in continuing
support of a NIDA-NIH Research
Center established here in 1987,
under the direction of RU Professor
Mary Jeanne Kreek, head of the
Laboratory of the Biology of
Addictive Diseases.
"We are absolutely thrilled to
receive this renewal grant," says
Kreek, who credits the center's
"talented team of scientists for work
ing tirelessly over the last two years"
to produce the successful proposal.
"This was an extremely
competitive process, but we received
outstanding reviews across the
board." The center, says Kreek, is
dedicated to identifying biological
correlates of addictions to heroin,
cocaine and alcohol-alone and
in combination with one another
while also studying other factors
that might affect treatment
outcomes.
"Effective treatments must be
based on a fundamental understand
ing of the molecular neurobiological
basis of each specific addictive
disease," she maintains, "as well as
of the effects of drugs of abuse and
any inherent and environmental
factors that may increase vulnerabili
ty prior to exposure to such drugs."
Over the next five years, the
NIDA grant will support the center's
core resources and six projects to be
undertaken by scientists in the
Kreek laboratory.-M. L.
SEARCH
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HONORS

Professors Jan Breslow and David D.
Ho were elected to the Institute of
Medicine of the U.S. National
Academy of Sciences. Breslow is head
of the Laboratory of Biochemical
Genetics and Metabolism. Ho is
scientific director of the Aaron
Diamond AIDS Research Center for
the City of New York.
A paper on Chagas' disease,
coauthored by Abby Rockefeller
Mauze Professor Joel E. Cohen,
head of the Laboratory of
Populations, was awarded the Fred
L. Soper Prize by the Pan American
Health and Education Foundation.
Associate Professor Robert Darnell,
head of the Laboratory of Neuro
Oncology, was named the ninth
recipient of the Derek Denny-Brown
Young Neurological Scholar Award
by the American Neurological
Association. The award goes annual
ly to "a newly elected member of the
association who is deemed to have
achieved a significant stature in
neurological research and whose

promise of continuing major contri
butions to the field of neurology is
anticipated."
Paul Greengard, Vincent Astor
Professor and head of the Laboratory
of Molecular and Cellular'
Neuroscience, received the 1997
Charles A. Dana Award for Pioneering
Achievements in Health, an accolade
that recognizes "outstanding accom
plishments that hold great potential
for fostering positive change in
health." He shared the award with
Trustee Eric R. Kandel, university
professor at Columbia University.
Alumnus Scott M. Grundy ('68)
was the winner of the 1997 Bristol
Myers Squibb/Mead Johnson Award
for Distinguished Achievement in
Nutrition Research.
Leon Hess Professor Hidesaburo
Hanafusa, head of the Jeanette
Warren Davidson Laboratory of
Molecular Oncology, was elected a
fellow of the American Academy of
Microbiology, the only honorific
leadership group devoted entirely to
microbiologists and the science of
microbiology.
Professor Mary E. Hatten, head of
the Laboratory of Developmental
Neurobiology, delivered the keynote
address at commencement at her
alma mater, Hollins College in
Virginia, where she was presented
with an honorary doctorate.
The Rockefeller University's Aaron
Diamond AIDS Research Center
(ADARC) was awarded a $500,000
Bristol-Myers Squibb Unrestricted
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Infectious Disease Research Grant to
help support studies on the dynam
ics of HIV replication. Professor and
ADARC Scientific Director David
Ho will supervise the grant. Ho,
who was honored by the New York
Academy of Medicine at its Fourth
Annual Gala Dinner, gave commence
ment addresses at Swathmore College
and at the Massachusetts Institute of
Technology, where President Clinton
also spoke.
Sherman Fairchild Professor
Attallah Kappas, head of the
Laboratory of Pharmacology, was
appointed to a six-year term as a
member of the Council of the State
University of New York (SUNY )
Health Sciences Center in Brooklyn,
N.Y. The council serves as the
governing body of the center, which
includes its medical school and
graduate education and hospital
facilities and is the largest health
science center in the SUNY system.
Professor and President Emeritus
Joshua Lederberg, head of the
Laboratory of Molecular Genetics
and Informatics, received an hon
orary Doctor of Military Medicine

degree from the Uniformed Services
University of the Health Sciences.
Alumnus Robert Mackel ('78),
adjunct faculty member in the
Asanuma laboratory, has been named
president of the Council for Higher
Education in Luxembourg. Charged
with advising the government on
policy decisions affecting higher edu
cation and scientific research, the
council is comprised of leaders from
academia, business and industry.

The National Alliance for Research
on Schizophrenia and Depression
(NARSAD) awarded Professor Bruce
McEwen, head of the Harold and
Margaret Milliken Hatch Laboratory
of Neuroendocrinology, a 1998

Distinguished Investigator grant and
named Assistant Professor Maria
Karayiorgou, head of the Laboratory
of Human Neurogenetics, and
Barbara Porton, postdoctoral associ
ate in the Laboratory of Molecular
and Cellular Neuroscience, recipients
of 1998 Young Investigat;r awards.
Bruce Merrifield, John D.
Rockefeller Jr. Professor Emeritus
and head of the Laboratory of
Biochemistry, and university Trustee
Ronald C. Breslow, professor of
chemistry at Columbia University;
were among the top 75 "distin
guished contributors to the chemical
enterprise" named by Chemical &
Engineering News, the news magazine
of the American Chemical Society.
Assistant Professor Peter Mombaerts,
head of the Laboratory of Vertebrate
Developmental Neurogenetics, was
named a Guggenheim Fellow by the
John Simon Guggenheim Memorial
Foundation. The fellowships are
awarded to individuals "who have
demonstrated exceptional capacity
for productive scholarship or excep
tional creative ability in the arts."
He also received a Scholar Award
from the Rita Allen Foundation and
was awarded a 1997 Presidential
Early Career Award for Scientists and
Engineers (PECASE), one of only 11
scientists to be granted the award by
President Clinton. Mombaerts is the
second Rocke£eller faculty member
to receive the award. Associate
Professor Ali Hemmati-Brivanlou,
head of the Laboratory of Molecular
Vertebrate Embryology, received a
PECASE in 1996.

Professor Michael O'Donnell, head
of the Laboratory of DNA
Replication and an HHMI investiga
tor, received a Method to Extend
Research in Time (MERIT) Award
from the National Institute of
General Medical Sciences at NIH in
support of his study "Biochemical
Mechanism of DNA Polymerase III
Holoenzyme."
Melissa Pope, assistant professor in
the Laboratory of Cellular Physiology
and Immunology; and Leonidas
Stamatatos, assistant professor and
staff scientist at the Aaron Diamond
AIDS Research Center, were named
winners of the American Foundation
for AIDS Research Award for their
innovative research on HIV vaccines.

Andrej Sali, assistant professor and
head of the Laboratory of Molecular
Biophysics, was awarded a 1998
Sloan Research Fellowship by the
Alfred P. Sloan Foundation.
President Emeritus Frederick Seitz
was awarded the Joseph Henry
Medal by the Smithsonian
Institution. The medal recognizes
SEARCH
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Markus Stoffel, assistant professor
and head of the Laboratory of
Metabolic Diseases, was appointed
the first Robert and Harriet
Heilbrunn Professor. The professor
ship provides support for a member
of the junior faculty conducting
research on diabetes.

PROMOTIONS

Seitz's "exemplary contributions to
the Smithsonian Institution."
Henry Kunkel Professor Ralph
Steinman, head of the Laboratory of
Cellular Physiology and Immunology,
received the Cancer Research
Institute's 1998 William B. Coley
Award for Distinguished Research in
Basic and Tumor Immunology.

TO PROFESSOR:

Steve DiNardo, head of the

Laboratory of Developmental and
Molecular Genetics.
Titia de Lange, head of the

Laboratory of Cell Biology and
Genetics.
TO ASSOCIATE PROFESSOR:

Yongwon Choi, head of the
Rong Wang, assistant professor in the
Laboratory for Mass Spectrometry
and Gaseous Ion Chemistry, received
a $150,000 grant from the
Alzheimer's Association to investigate
the role of metabolism of amyloid
beta-protein in Alzheimer's disease.

President Torsten Wiesel is the
recipient of The New York Academy
of Medicine's 1998 John Stearns
Award for Lifetime Achievement in
Medicine. Presented at the acade
my's 1998 Spring Stated Meeting,
the award recognizes Wiesel's "pio
neering studies of the mammalian
visual cortex, [ which] have signifi
cantly shaped current understanding
of brain structure, function and
development."
Alumnus Cecil Cheung-Ching Yip
('63) received a McMaster Award for
Science for contributions to insulin
research.
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Laboratory of Immunology.
Robert B. Darnell, head of the

Laboratory of Molecular Neuro
Oncology.
Seth Darst, head of the Laboratory
of Molecular Biophysics.
Ali Hemmati-Brivanlou, head of the

Laboratory of Molecular Vertebrate
Embryology.
David S. Thaler, member of the

Laboratory of Molecular Genetics
and Informatics.
ADMINISTRATION

The board of trustees presented
the David Rockefeller Award for
Extraordinary Service to The
Rockefeller University to university
Trustee John C. Whitehead and
David J.L. Luck, the late Alfred E.
Mirsky Professor and vice president
for academic affairs, who died May

23, 1998 (see In Memoriam, next
page). The award recognizes an indi
vidual from the RU community who
exhibits an enthusiasm for RU's
scientists and their research, dedica
tion to furthering the university's
mission and strengthening the
institution, and encourages others to
support the biomedical sciences for
the benefit of humankind. It was
established and first presented in June
1995 to David Rockefeller, in honor
of his 55 years of distinguished ser
vice on the board of trustees.
Life Trustees Brooke Astor and
David Rockefeller were each award
ed a Medal of Freedom, the nation's
highest civilian honor, by President
Clinton.
RU Trustee and Adjunct Professor
Alexander G. Bearn has been

named executive officer of the
American Philosophical Society, the
oldest U.S. learned society, founded

by Benjamin Franklin in 1743 to
"promote useful knowledge" in
science and the humanities.
Science Outreach Program Director
Bonnie Kaiser was elected director
at-large of the American Chemical
Society's New York Section for 1998.
David J. Lyons, senior advisor to
the president and retired vice presi
dent for business and finance and
treasurer at RU, received the
National Association of College and
University Business Officers 1997
Distinguished Business Officer
Award.
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Research Associate Marguerite
Mangin is now associate dean of
graduate studies. She was previously
assistant dean. Associate Professor
Thomas P. Sakmar, head of the
Laboratory of Molecular Biology and
Biochemistry and an associate inves
tigator with HHMI, has been named
associate dean of graduate studies,
with special responsibility for
Rockefeller's participation in the Tri
institutional M.D.-Ph.D. Program.
Kenneth W Rose, assistant to the
director of the Rockefeller Archive
Center, has been awarded a Fulbright
grant by the United States Information
Agency to teach American history
and American studies at Ege
University in Izmir, Turkey.

IN MEMORIAM

DAVID J.L. LUCK
The Rockefeller University commu
nity is mourning the loss of David
J.L. Luck, Alfred E. Mirsky Professor
and vice president for academic
affairs, who died Saturday, May 23,
at New York Hospital. He was 69
years old. T he cause of death was
lymphoma.
Luck was a medically trained
researcher with a keen interest in
basic science. After earning a med
ical degree from Harvard Medical
School and clinical training at
Massachusetts General Hospital
(MGH), Luck came to Rockefeller as
a graduate fellow in 1958, where he
joined the cell biology laboratory of
Nobel laureate George E. Palade.
His early research focused on how
growing cells form mitochondria,
structures contained in the body of
the cell that produce metabolic ener
gy. In 1962, Luck and Rockefeller
biochemist Edward Reich, working
with the simple mold Neurospora,
were among the first to discover that
mitochondria contain their own
DNA, distinct from the DNA found

in the cell nucleus. He established the
existence within mitochondria of a
class of ribosomes-RNA-protein
complexes that are the sites for pro
tein synthesis-that can serve as a
means for converting the genetic
information of this unique DNA into
protein. In the late 1970s, Luck
showed that one ribosomal protein, a
component of the small subunit of
the ribosome, was made within mito
chondria and regulated the entire
assembly process of protein synthesis.
Luck's later research focused on
microtubules, the dynamic skeletal
structures that assist cells in move
ment, communication with other
cells and division. Using the single
celled aquatic alga Chlamydomonas
as a model organism, Luck and his
associates were able to identify and
study the function of some of the
more than 200 accessory proteins
that are present in flagella and cilia.
His investigations of microtubules
in Chlamydomonas provided a
methodological framework for nego
tiating the far more complex micro
tubular systems in human cells and
toward establishing possible links
between microtubular failure and
lung, reproductive or neurological
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disorders, or in the cell-division
defects in cancer.
Luck received a medical degree
from Harvard Medical School in
1953. Except for two years of med
ical service with the United States
Air Force, he was on the staff of
MGH between 1953 and 1958 as
intern, assistant resident, physician
and resident physician.
Luck received his doctoral degree
from Rockefeller in 1962 and
became a research associate. He was
appointed assistant professor in
1964, associate professor in 1966
and professor in 1968. In 1985 he
was named the university's first
Alfred E. Mirsky Professor, and in
1994, vice president for academic
affairs.
Luck was elected to membership
in the U.S. National Academy of
Sciences in 1984 and was a fellow
of the American Association for the
Advancement of Science.
He was a member of the Medical
Advisory Board of the Howard
Hughes Medical Institute (HHMI)
and served on the Scientific Review
Boards of HHMI (1989 to 1993) and
the Massachusetts General Hospital
(1989 to 1992).
J. RICHARDSON DILWORTH
Trustee Emeritus J. Richardson
Dilworth died of complications from
heart surgery on Dec. 29, 1997, at
Princeton Hospital in Princeton,
N.J. He was 81. A noted philan
thropist and financier, Dilworth
served RU as a trustee from 1960 to
1991. As treasurer and chairman of
the university's finance and invest
ment committee, he helped to
ensure the financial health of the
institution and oversaw a fourfold
growth of its endowment. Dilworth
played a key role in the develop
ment of housing for students and
faculty, as well as the construction
of new laboratory buildings that
•
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transformed the south e'nd of
campus into a modern biomedical
research complex. In 1992 Dilworth
was named a trustee emeritus and
the following year he was awarded
an honorary doctor of science
degree in recognition of his out
standing service to The Rockefeller
University community. At the time
of his death, he was on the board of
directors of AEA Incorporated, a
private investment company he
helped to found.
KEITH R. PORTER
Keith R. Porter, a former member
and professor of the Rockefeller
Institute for Medical Research who
is widely recognized as a founding
father of modern cell biology, died
May 2, 1997. Porter joined
Rockefeller as a research assistant in
1939. In 1953, he became the head
of the Laboratory of Cytology, later
renamed the Laboratory of Cell

Biology. While at RU, Porter
cocreated the first electron micro
graph of an intact cell, along with
Albert Claude and Ernest Fullam.
Later, Porter identified the cell's
endoplasmic reticulum, elucidated
the structure of collagen fibers, cilia
and microtubules, and defined the
microtrabecular lattice. His innova
-tive methodology for the use of the
electron microscope, design of the
Porter-Blum microtome and tech
niques for tissue culturing opened
up the field of cell biology by allow
ing much greater insight into the
structure and function of cells.
In 1955, Porter founded the
Journal of Cell Biology, which is
published by the RU Press. He
founded the Tissue Culture
Association in 1946, and in 1961 he
cofounded and became the first
president of the American Society
for Cell Biology Porter was a mem
ber of the National Academy of
Sciences and received the National
Medal of Science. After leaving RU,
Porter established laboratories of
cell biology at Harvard University,
the University of Colorado and the
University of Maryland. He was a
professor emeritus at the University
of Pennsylvania when he died.
NAN CY DICKERSON
WHITEHEAD
RU Council member Nancy
Dickerson Whitehead died at age 70
on Oct. 18, 1997, of stroke compli
cations at New York Hospital. The
wife of RU Trustee John Whitehead,
she also served on the boards of
Covenant House, the Hospital for
Special Surgery and the New York
Public Library and was a member of
the Central Park Conservancy.

For continually updated information
about RU, visit our web page:
http://www. rockefeller.edul.
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A ball-and-stick model of a potassium ion
channel from the bacterium Streptomyces
lividans shows a potassium ion (red sphere)
inside the pore. The protein is comprised of
four identical subunits that join together like
the staves of a barrel around the central pore.
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